G

GT Biopharma

GTBP

2.59000
USD
0.05
(1.97%)
Market Closed
Volume
36
EPS
0
Div Yield
0
P/E
-0
Market Cap
6,881,730
Related Instruments
A
ACST
0.05000
(1.87%)
2.73000 USD
C
CEI
-0.00140
(-1.14%)
0.12100 USD
H
HUSA
-0.10000
(-7.30%)
1.27000 USD
P
PSTV
0.00000
(0.00%)
1.80000 USD
P
PTN
-0.03000
(-1.79%)
1.65000 USD
S
SNDL
-0.07000
(-3.08%)
2.20000 USD
W
WTER
0
(0%)
0.000000 USD
News

Title: GT Biopharma

Sector: Healthcare
Industry: Biotechnology
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.